While having the FA suggest increasing the size of the trial....thus making it take longer....this might be a positive from a scientific stand point....and if BDZ says its a positive from that angle then I believe it.  

But that's not why I don't want to see it happen.....my concern is about how the market would react.  RVX is already in something of a cash crunch, at least according to all the information available in the public domain.  We just saw the PPS get punished in the wake of the $10 million financing news....I happen to think that short selling was the major culprit for the dive, but whatever the reason behind the drop....the PPS went as low as $1.23 

If the FA comes with a reccomendation to dose more patients, that increases the cost of the trial.....and I can easily envision another pounding on the PPS.  Whether it would be because of shareholders bailing out, or manipulative short selling....either way I can see the PPS taking another big hit.

That's why I'm hopeful for a thumbs up, stay the course result.